User:Mr. Ibrahem/Tick-borne encephalitis vaccine

Tick-borne encephalitis vaccine is a vaccine used to prevent tick-borne encephalitis (TBE). The disease is most common in Central and Eastern Europe, and Northern Asia. More than 87% of people who receive the vaccine develop immunity. It is not useful following the bite of an infected tick. It is given by injection into a muscle.

The World Health Organization (WHO) recommends immunizing all people in areas where the disease is common. Otherwise the vaccine is just recommended for those who are at high risk. Three doses are recommended followed by additional doses every three to five years. The vaccines can be used in people more than one or three years of age depending on the formulation. The vaccine appears to be safe during pregnancy.

Serious side effects are rare. Restlessness is an uncommon side effect in children. Minor side effects may include fever, and redness and pain at the site of injection. Older formulations were more commonly associated with side effects. All tick-borne encephalitis vaccines are inactivated whole virus alum-adjuvanted vaccines.

The first vaccine against TBE was developed in 1937. It is on the World Health Organization's List of Essential Medicines. Per dose it costs £30 in the United Kingdom as of 2021. The vaccine is not available in the United States. Two types are available in Russia and two in Europe.